Metabonomics in pharmaceutical discovery and development.
Metabonomics has emerged as a key technology in pharmaceutical discovery and development, evolving as the small molecule counterpart of transcriptomics and proteomics. In drug discovery laboratories, metabonomics aids in target identification, phenotyping, and the understanding of the biochemical basis of disease and toxicity. This review focuses on three areas where metabonomics is used in the industry: (1) analytical considerations, (2) chemometric and statistical concerns, and (3) biological aspects and applications.
Robertson
Donald G
DG
Metabonomics Evaluation Group, Pfizer Global Research and Development, 2800 Plymouth Road, Ann Arbor, MI 48105, USA. donald.robertson@pfizer.com
Reily
Michael D
MD
Baker
J David
JD
D000818:Animals; D004358:Drug Therapy; D006801:Humans; D009682:Magnetic Resonance Spectroscopy; D023421:Models, Animal; D004364:Pharmaceutical Preparations / Q000737:chemistry* / Q000378:metabolism*; D011506:Proteins / Q000235:genetics* / Q000378:metabolism; D051381:Rats; D014158:Transcription, Genetic
D004364:Pharmaceutical Preparations; D011506:Proteins